Literature DB >> 19561858

Nebivolol (bystolic), a novel Beta blocker for hypertension.

Olga Hilas1, Danielle Ezzo.   

Abstract

Entities:  

Year:  2009        PMID： 19561858      PMCID： PMC2697096     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  19 in total

Review 1.  Expert consensus document on beta-adrenergic receptor blockers.

Authors:  José López-Sendón; Karl Swedberg; John McMurray; Juan Tamargo; Aldo P Maggioni; Henry Dargie; Michal Tendera; Finn Waagstein; Jan Kjekshus; Philippe Lechat; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

Review 2.  Nebivolol: a review of its use in the management of hypertension and chronic heart failure.

Authors:  Marit D Moen; Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).

Authors:  J Coresh; G L Wei; G McQuillan; F L Brancati; A S Levey; C Jones; M J Klag
Journal:  Arch Intern Med       Date:  2001-05-14

4.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study.

Authors:  B M Psaty; C D Furberg; L H Kuller; M Cushman; P J Savage; D Levine; D H O'Leary; R N Bryan; M Anderson; T Lumley
Journal:  Arch Intern Med       Date:  2001-05-14

Review 5.  Pharmacology of nebivolol.

Authors:  M Mangrella; F Rossi; F Fici; F Rossi
Journal:  Pharmacol Res       Date:  1998-12       Impact factor: 7.658

6.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

Review 7.  Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs.

Authors:  B N Prichard
Journal:  Am J Cardiol       Date:  1987-05-15       Impact factor: 2.778

Review 8.  Established risk factors and coronary artery disease: the Framingham Study.

Authors:  P W Wilson
Journal:  Am J Hypertens       Date:  1994-07       Impact factor: 2.689

Review 9.  Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.

Authors:  L Michael Prisant
Journal:  J Clin Pharmacol       Date:  2007-12-14       Impact factor: 3.126

10.  The efficacy and tolerability of nebivolol in hypertensive African American patients.

Authors:  Elijah Saunders; William B Smith; Karen B DeSalvo; Will A Sullivan
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738
View more
  10 in total

Review 1.  Hypertension in African Americans.

Authors:  Nomsa Musemwa; Crystal A Gadegbeku
Journal:  Curr Cardiol Rep       Date:  2017-10-28       Impact factor: 2.931

Review 2.  β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature.

Authors:  James J DiNicolantonio; Hassan Fares; Asfandyar K Niazi; Saurav Chatterjee; Fabrizio D'Ascenzo; Enrico Cerrato; Giuseppe Biondi-Zoccai; Carl J Lavie; David S Bell; James H O'Keefe
Journal:  Open Heart       Date:  2015-03-21

Review 3.  Pharmacological update: New drugs in cardiac practice: A critical appraisal.

Authors:  Rohan Magoon; Arindam Choudhury; Vishwas Malik; Ridhima Sharma; Poonam Malhotra Kapoor
Journal:  Ann Card Anaesth       Date:  2017-01

4.  A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.

Authors:  Nithishwer Mouroug Anand; Devang Haresh Liya; Arpit Kumar Pradhan; Nitish Tayal; Abhinav Bansal; Sainitin Donakonda; Ashwin Kumar Jainarayanan
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

5.  FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.

Authors:  Mengmeng Niu; Jing Xu; Yang Liu; Yuhuang Li; Tao He; Liangping Ding; Yajun He; Yong Yi; Fengtian Li; Rongtian Guo; Ya Gao; Rui Li; Luping Li; Mengyuan Fu; Qingyong Hu; Yangkun Luo; Chunyan Zhang; Kewei Qin; Jianqiao Yi; Shuhan Yu; Jian Yang; Hu Chen; Liang Wang; Zhonghan Li; Biao Dong; Shiqian Qi; Liang Ouyang; Yujun Zhang; Yang Cao; Zhi-Xiong Jim Xiao
Journal:  Nat Commun       Date:  2021-10-11       Impact factor: 14.919

6.  The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension.

Authors:  Regina Pawlak-Chomicka; Tomasz Krauze; Pawel Uruski; Jaroslaw Piskorski; Andrzej Wykretowicz; Andrzej Tykarski; Przemyslaw Guzik
Journal:  Cardiol Res Pract       Date:  2022-03-31       Impact factor: 1.866

7.  Investigation of the Potential of Nebivolol Hydrochloride-Loaded Chitosomal Systems for Tissue Regeneration: In Vitro Characterization and In Vivo Assessment.

Authors:  Noha Ibrahim Elsherif; Abdulaziz Mohsen Al-Mahallawi; Abdelfattah Ahmed Abdelkhalek; Rehab Nabil Shamma
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

8.  Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers.

Authors:  Corina Briciu; Maria Neag; Dana Muntean; Corina Bocsan; Anca Buzoianu; Oana Antonescu; Ana-Maria Gheldiu; Marcela Achim; Adina Popa; Laurian Vlase
Journal:  Clujul Med       Date:  2015-04-15

9.  Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation.

Authors:  Anroop B Nair; Jigar Shah; Bader M Aljaeid; Bandar E Al-Dhubiab; Shery Jacob
Journal:  Polymers (Basel)       Date:  2019-10-16       Impact factor: 4.329

Review 10.  Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.

Authors:  Waleed AlHabeeb; Sanaa Mrabeti; Ahmed Adel Ibrahim Abdelsalam
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-09       Impact factor: 3.947
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.